Court Orders Permanent Injunction Against NeoGenomics'; Accused RaDaR Assay, as Case Enters New Phase
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has provided an update on its patent infringement litigation against NeoGenomics. On September 23, 2024, the District Court for the Middle District of North Carolina issued a permanent injunction against NeoGenomics' accused RaDaR assay, following a preliminary injunction from December 2023.
Natera is continuing to pursue its claim against a modified version of RaDaR for infringement of Natera's '454 patent. The company is seeking full remedies, including injunctive relief, especially after the Patent Office denied NeoGenomics' petition for 'inter partes' review challenging the validity of the '454 patent.
Natera, Inc. (NASDAQ: NTRA), un leader nel settore dei test del DNA libero, ha fornito un aggiornamento sulla sua causa per violazione di brevetto contro NeoGenomics. Il 23 settembre 2024, il Tribunale Distrettuale per il Distretto Centrale della Carolina del Nord ha emesso un ingiunzione permanente contro il test RaDaR accusato di NeoGenomics, a seguito di un'ingiunzione preliminare del dicembre 2023.
Natera continua a perseguire il suo reclamo contro una versione modificata di RaDaR per violazione del brevetto '454 di Natera. L'azienda sta cercando rimedi completi, inclusa la protezione mediante ingiunzione, specialmente dopo che l'Ufficio Brevetti ha negato la petizione di NeoGenomics per una revisione 'inter partes' che contestava la validità del brevetto '454.
Natera, Inc. (NASDAQ: NTRA), un líder en pruebas de ADN libre, ha proporcionado una actualización sobre su litigio por infracción de patente contra NeoGenomics. El 23 de septiembre de 2024, el Tribunal de Distrito del Distrito Medio de Carolina del Norte emitió una orden de restricción permanente contra el ensayo RaDaR acusado de NeoGenomics, tras una orden de restricción preliminar de diciembre de 2023.
Natera sigue persiguiendo su demanda contra una versión modificada de RaDaR por infracción de la patente '454 de Natera. La compañía busca remedios completos, incluyendo alivio mediante orden de restricción, especialmente después de que la Oficina de Patentes negó la petición de NeoGenomics para una revisión 'inter partes' que desafiaba la validez de la patente '454.
Natera, Inc. (NASDAQ: NTRA)는 무혈액 DNA 테스트의 선두주자로서 NeoGenomics에 대한 특허 침해 소송의 업데이트를 제공했습니다. 2024년 9월 23일, 노스 캐롤라이나 중부 지방법원은 NeoGenomics의 RaDaR 분석에 대해 영구적 금지 명령을 내렸으며, 이는 2023년 12월에 발행된 임시 금지 명령에 따른 것입니다.
Natera는 Natera의 '454 특허를 침해한 수정된 RaDaR 버전에 대한 청구를 계속 진행하고 있습니다. 회사는 특히 특허청이 '454 특허의 유효성을 문제 삼는 NeoGenomics의 청원 요청을 거부한 이후로, 금지 명령을 포함한 전면적인 구제를 청구하고 있습니다.
Natera, Inc. (NASDAQ: NTRA), un leader dans le domaine des tests ADN libres, a fourni une mise à jour sur son litige pour violation de brevet contre NeoGenomics. Le 23 septembre 2024, le tribunal de district du district moyen de Caroline du Nord a émis une injonction permanente contre le test RaDaR de NeoGenomics, à la suite d'une injonction préliminaire en décembre 2023.
Natera poursuit toujours sa réclamation contre une version modifiée de RaDaR pour violation du brevet '454 de Natera. La société recherche des recours complets, y compris une réparation par injonction, surtout après que l'Office des brevets a rejeté la pétition de NeoGenomics pour une révision 'inter partes' contesté la validité du brevet '454.
Natera, Inc. (NASDAQ: NTRA), ein führendes Unternehmen im Bereich getesteter zellfreier DNA, hat ein Update zu seinem Patentverletzungsverfahren gegen NeoGenomics bereitgestellt. Am 23. September 2024 erließ das Amtsgericht für den Mittleren Bezirk von North Carolina eine dauerhafte Einstweilige Verfügung gegen das angeklagte RaDaR-Tests von NeoGenomics, nachdem eine vorläufige Verfügung im Dezember 2023 erlassen worden war.
Natera verfolgt weiterhin seine Klage gegen eine modifizierte Version von RaDaR wegen Verletzung des '454 Patents von Natera. Das Unternehmen strebt vollständige Rechtsmittel an, einschließlich Unterlassungsansprüche, insbesondere nachdem das Patentamt den Antrag von NeoGenomics abgelehnt hat für eine 'inter partes' Überprüfung, die die Gültigkeit des '454 Patents in Frage stellte.
- Permanent injunction granted against NeoGenomics' accused RaDaR assay
- Patent Office denied NeoGenomics' petition challenging Natera's '454 patent validity
- Natera continues to pursue claims against modified RaDaR version
- None.
Insights
The court's decision to issue a permanent injunction against NeoGenomics' RaDaR assay marks a significant victory for Natera in this ongoing patent infringement case. This ruling effectively prevents NeoGenomics from selling or using the accused RaDaR assay, which could substantially impact their market position in the liquid biopsy space.
The denial of NeoGenomics' petition for 'inter partes' review by the Patent Office further strengthens Natera's position, as it upholds the validity of their '454 patent. This development allows Natera to continue pursuing claims against a modified version of RaDaR, potentially extending their legal advantage.
For investors, this outcome could translate to increased market share and revenue opportunities for Natera, while posing significant challenges for NeoGenomics in the competitive landscape of genetic testing. The ongoing litigation and potential for additional injunctive relief against modified versions of RaDaR could have long-term implications for both companies' strategic positioning and financial performance in the rapidly growing liquid biopsy market.
This legal victory for Natera could have substantial financial implications. By securing a permanent injunction against a competitor's product, Natera potentially eliminates a direct threat to its market share in the liquid biopsy segment. This could lead to:
- Increased revenue opportunities as customers may shift to Natera's products
- Potential for higher profit margins due to reduced competitive pressure
- Enhanced investor confidence, possibly leading to a positive impact on stock valuation
However, it's important to consider the ongoing costs of litigation and the potential for appeals. The continuation of the case against the modified RaDaR version suggests that legal expenses will persist. Investors should monitor how this impacts Natera's operating expenses and overall profitability in the coming quarters.
Additionally, this development may spur increased R&D investment from competitors seeking to develop non-infringing alternatives, potentially intensifying competition in the long term. Overall, while the short-term outlook appears positive for Natera, the long-term market dynamics remain complex and warrant close observation.
On Sept. 23, 2024, the District Court for the Middle District of
About Natera
NateraTM is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 200 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to developments in matters under dispute or litigation, or the scope of protection we establish and maintain for, and developments or disputes concerning, our intellectual property or other proprietary rights. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923199827/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
FAQ
What court decision was made regarding Natera's patent infringement case against NeoGenomics on September 23, 2024?
What is the status of Natera's (NTRA) claim against the modified version of NeoGenomics' RaDaR assay?
What was the outcome of NeoGenomics' petition to the Patent Office regarding Natera's (NTRA) '454 patent?
What remedies is Natera (NTRA) seeking in its ongoing patent infringement case against NeoGenomics?
